VOZMOZhNOSTI NEFROPROTEKTsII U PATsIENTOV S METABOLIChESKIM SINDROMOM
- Authors: Nedogoda SV1
-
Affiliations:
- Issue: No 2 (2009)
- Pages: 26-30
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245804
- ID: 245804
Cite item
Full Text
Abstract
Along with cardiovascular complications renal impairment is one of the most prognostic unfavorable metabolic syndrom's consequence. Approaches to chronic kidney disease progression in patients with metabolic syndrome are discussed
References
- Mailloux L.U. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001;21:146-56.
- Kidney Disease Outcomes Quality Initiative (K/DOQI). Clinical practice guidelines on hypertension and antihy-pertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 Suppl. 1):S1-290.
- Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Invest Drugs 2000;9:2593-600.
- Joles J.A., Koomans H.A. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706.
- Ligtenberg G., Blankestijn P.J., Oey P.L., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-28.
- Grisk O., Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 2004;61:238-46.
- Wenzel R. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy Drugs 2005;65(Suppl. 2):29-39.
- Rubio-Guerra A.F., Trevino-Gomezharper C., Rodriguez-Lopez L., et al. Renoprotective effects of the combination trandolapril/verapamil in petints with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002;22(8):541-46.
- Rubio-Guerra A.F., Rodriguez-Lopez L., Arceo-Navarr A., et al. The effect of trandolapril and its fixed-dose combination with verapamil on the proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004;27(8):1688-91.
- The PROCOPA study group Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002;20:729-37.
- Schneider M., Lerch M., Papiri M., et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1995;14:669-77.
- Fernandez R., Puig J.G., Rodrigues-Perez J.C., et al. Effects of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001;15:849-56.
Supplementary files
